| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193057 | Journal of Thoracic Oncology | 2015 | 9 Pages |
Abstract
From a societal perspective, our cost-effectiveness results support the value of multiplexed genetic screening and molecularly guided therapy in metastatic NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Dorothy PhD, Stephanie MD, David PhD, Mary Beth PhD, Neal I. MD, G. Scott MD, PhD,